Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing technologies to assist and enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Group 1 - Proactive specializes in providing fast, accessible, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team operates from key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Group 2 - Proactive employs technology to enhance workflows and has a forward-looking approach to technology adoption [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Points - NanoViricides, Inc. has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 [1] - The filing was submitted to the Securities and Exchange Commission (SEC) on November 14, 2025 [1]

Financial Performance - The Company reported a net loss per common share for the three months ended September 30, 2025, with basic and diluted calculations reflecting the potential dilution from outstanding shares[38]. - The Company raised approximately $1,245,000 in net proceeds from the sale of 824,535 shares of common stock at an average price of $1.45 per share from July 1, 2025, to September 30, 2025[58]. - The Company sold 440,453 shares of common stock at an average price of approximately $1.55 per share from October 1, 2025, to November 4, 2025, generating net proceeds of approximately $663,000[73]. - On November 10, 2025, the Company entered into a securities purchase agreement to sell 1,970,000 shares of common stock at an offering price of $1.68 per share, with gross proceeds of approximately $6 million[74]. Research and Development - For the three months ended September 30, 2025, research and development costs related to TheraCour amounted to $539,522, a decrease from $644,527 in the same period of 2024, indicating a reduction of approximately 16.3%[47]. - The Company is dependent on its license agreements with TheraCour, which are critical for the development of its drug candidates[68]. - The Company has entered into multiple license agreements, including a COVID-19 License Agreement with TheraCour, which allows the Company to use proprietary technology for drug development[69]. - The Company will pay KMPL a royalty of 70% of the final invoiced sales of any resulting approved drugs from its clinical test drug candidates for COVID-19 in India[70]. Assets and Liabilities - The total property and equipment as of September 30, 2025, was $15,107,567, an increase from $15,023,250 as of June 30, 2025, reflecting a growth of approximately 0.56%[52]. - The Company’s intangible assets, net, as of September 30, 2025, totaled $314,971, a slight decrease from $317,039 as of June 30, 2025[53]. - The Company’s accumulated depreciation for property and equipment increased to $8,320,111 as of September 30, 2025, from $8,189,359 as of June 30, 2025, indicating an increase of approximately 1.6%[52]. - The Company’s accounts payable to TheraCour as of September 30, 2025, was $663,776, an increase from $584,089 as of June 30, 2025[46]. - As of September 30, 2025, accrued expenses totaled $26,300, an increase from $25,969 as of June 30, 2025[57]. Stock and Equity - The Company has 916,308 shares of Series A preferred stock outstanding, which can convert to 3,207,078 common shares only upon a change of control[39]. - The Company granted Dr. Anil Diwan 10,204 shares of Series A preferred stock, with a non-cash compensation expense of $10,013 recognized for the three months ended September 30, 2025[59]. - The Company issued 117,208 fully vested shares of common stock for consulting and legal services, recording an expense of $173,850 for the three months ended September 30, 2025[62]. - The Company has 5,434 outstanding and exercisable common stock warrants as of September 30, 2025, with a weighted average exercise price of $2.36[64]. Regulatory and Reporting - The Company adopted ASU 2023-07 for segment reporting, effective January 1, 2024, which requires additional disclosures regarding significant segment expenses[42]. - The private placement of Warrants and shares was conducted under an exemption from registration, indicating a strategic move to raise capital without extensive regulatory requirements[75]. - The company qualifies as a smaller reporting company and is not obligated to disclose certain market risk information, reflecting its operational scale[323].

Core Viewpoint - NanoViricides, Inc. is a clinical stage company focused on developing broad-spectrum antiviral drugs that are designed to be effective against viruses without the risk of escape [1] Group 1: Event Information - NanoViricides will present at the Pharma Partnering Summit 2025 on November 14, 2025, from 11:25 am to 11:45 am ET [1] - The event will take place at the Hilton Boston Logan Airport in Boston, MA [1]

Group 1 - Proactive specializes in providing fast, accessible, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team operates from key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Group 2 - The company employs technology to enhance workflows and improve content production [4] - Proactive utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Points - NanoViricides, Inc. has completed a securities purchase agreement with a healthcare institutional investor [1] - The agreement involves the purchase of 3,571,429 shares of common stock at a price of $1.68 per share [1] - The gross proceeds from this offering amount to approximately $6 million before expenses [1]

Group 1 - Proactive specializes in providing fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Points - NanoViricides, Inc. has entered into a securities purchase agreement with a healthcare institutional investor for the sale of 3,571,429 shares of common stock at a price of $1.68 per share [1] - The gross proceeds from this registered direct offering are expected to be approximately $6 million, before deducting placement agent commissions and other offering expenses [1] Company Summary - The offering involves the sale of common stock or common stock equivalents [1] - The transaction is structured as a registered direct offering, indicating a streamlined process for raising capital [1]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive specializes in medium and small-cap markets while also keeping the community updated on blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4] - Automation and software tools, including generative AI, are utilized, but all content is edited and authored by humans [5]